Home » Topics » BioWorld Science

BioWorld Science
RSS

Paratek Pharmaceuticals submits omadacycline NDAs in U.S.

Feb. 6, 2018

Oricula Therapeutics cleared to begin clinical testing of ORC-13661 in U.S.

Feb. 6, 2018

TBX15 identified as predictor of poor survival in HCC patients

Feb. 6, 2018

FDA expands indication for AMAG's Feraheme

Feb. 6, 2018

Acticor Biotech's phase I study of ACT-017 meets endpoints

Feb. 6, 2018

SapVax announces its most recent achievements

Feb. 6, 2018

Phase III ADVANCE study of Rolontis meets primary endpoint

Feb. 6, 2018

Topline results from phase IIb study of EGP-437

Feb. 6, 2018

IRLAB provides update on its lead development programs, IRL-752 and IRL-790

Feb. 6, 2018

Ozempic and Fiasp launched in the U.S.

Feb. 6, 2018

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 14, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 14, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...